WCLC 2022 Conference Coverage


 

Lacture Summary - WCLC 2022 on the Single Arm Phase II Study PEMMELA: Pembrolizumab + Lenvatinib in 2L/3L Malignant Pleural Mesothelioma Patients

11 views
August 18, 2022
Comments 0
Login to view comments. Click here to Login